IMR Press / EJGO / Volume 28 / Issue 3 / pii/2007142

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Weekly paclitaxel in the treatment of recurrent ovarian carcinoma

Show Less
1 Cancer Research UK, Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK
Eur. J. Gynaecol. Oncol. 2007, 28(3), 174–178;
Published: 10 June 2007

Purpose: To study the effect of weekly paclitaxel in the treatment of recurrent ovarian and peritoneal carcinoma. Methods: A retrospective analysis of patients treated at Christie Cancer Centre between May 2003 and May 2005 was carried out. Results: Forty­nine patients with recurrent ovarian and peritoneal carcinoma were treated. The mean duration of treatment was 11 weeks, with 27 (54%) patients receiving 12 or more treatments. The most frequent non-haematological toxicities reported were mild nausea, constipation, lethargy and neuropathy. Moderate anaemia was noted in 50% of patients. Radiological assessment by CT scanning showed that complete or partial responses were achieved in 28% of patients. CA125 response was demonstrated in 63% of patients. Median time to recurrence was I 49 days and median survival was 359 days. Conclusion: This study provides evidence for the role of weekly paclitaxel in the treatment of recurrent ovarian and peritoneal carcinoma even in a drug-resistant setting following mul­tiple lines of prior therapy.

Recurrent ovarian carcinoma
Recurrent peritoneal carcinoma
Back to top